WildMil Therapeutics announced that cofounder Kimberly Noonan, Ph.D, MPH, has been named EVP, chief science and technology officer. 

“It’s an exciting time at WindMil, with the ongoing enrollment of our Phase II NSCLC clinical trial and data from our pre-clinical CAR-MILs research with Penn now reading out,” Noonan said in a statement. “I’m honored to broaden my work with the team as we continue to advance MILs programs into the clinic with the goal of creating life-saving therapies for patients with cancer.”